---
title: "Unable to Access CMAJ Practice Article on Rheumatoid Arthritis — Source Blocked"
id: "cmaj-2-rheumatoid-arthritis-practice"
canonical_url: "https://medichelpline.com/clinical-feed/cmaj-2-rheumatoid-arthritis-practice"
content_type: "clinical_feed_article"
specialty: "Rheumatology"
source_name: "CMAJ"
source_url: "http://www.cmaj.ca/cgi/content/short/198/40/E1535?rss=1"
published_at: "2026-11-16T05:05:19.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Unable to Access CMAJ Practice Article on Rheumatoid Arthritis — Source Blocked
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/cmaj-2-rheumatoid-arthritis-practice
- **Specialty:** [Rheumatology](https://medichelpline.com/clinical-feed/rheumatology.md)
- **Primary Source:** CMAJ
- **Source URL:** [Original Journal Publication](http://www.cmaj.ca/cgi/content/short/198/40/E1535?rss=1)
- **Published At:** 2026-11-16T05:05:19.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
- The source link to CMAJ returned a site block and did not deliver the practice article content on **rheumatoid arthritis**. The blocked page is the only text available from the source. - The Cloudflare block message appeared; investigators (the site) reported a security service prevented access. No clinical data, trial results, or practice recommendations were accessible from the provided URL. - The source did not report any methodology, patient cohorts, dosing, endpoints, or outcome measures because the article text was unavailable behind the block. - The published page included a Cloudflare Ray ID and an instruction to contact the site owner to resolve the block; no clinical content accompanied that notice. - For clinicians seeking the original CMAJ practice content, practical next steps include contacting site support, using institutional access, or requesting the article through interlibrary loan; the source itself did not offer alternative retrieval instructions. - Because the source lacked clinical content, no evidence-based practice changes or guideline-level recommendations can be extracted or summarized from it. The absence of accessible data leaves specific clinical questions unanswered. - Any attempt to report clinical findings, numbers, or trial details would require accessing the full article; the current source does not permit such verification and thus precludes safe clinical reporting. - The immediate limitation is documented: blocked access prevented appraisal. The unresolved questions are operational (how to obtain the article) and clinical (what the article would have reported), both stemming directly from the block.
## Clinical Analysis & Structured Key Points
[ Skip to main content ](https://www.cmaj.ca/content/198/40/E1535#main-content) [![top-left](https://www.cmaj.ca/sites/default/files/2025-06/cmaj-logo_publisher.png) ](https://www.cmaj.ca/) ## Umbrella menu * [CMAJ Open](http://www.cmajopen.ca) * [CJS](http://www.canjsurg.ca) * [JAMC](https://www.cmaj.ca/page/apropos) * [Log in](https://www.cmaj.ca/openid-connect/sams-sigma/login-redirect?prompt=login&openid_connect_destination=/content/198/40/E1535) Toggle navigation menu Open settings menu Open search [![logo](https://www.cmaj.ca/sites/default/files/logo/cmaj-rgb_new_0_18.png)](https://www.cmaj.ca/) [![logo](https://www.cmaj.ca/sites/default/files/2025-05/cmaj-rgb_new.png)](https://www.cmaj.ca/) [ Advanced Search ](https://www.cmaj.ca/search) ## Main navigation * [Home](https://www.cmaj.ca/) * [Content](https://www.cmaj.ca/content/current) * [Current Issue](https://www.cmaj.ca/content/current) * [Past issues](https://www.cmaj.ca/content/by/year) * [Early releases](https://www.cmaj.ca/earlyrelease) * [Collections](https://www.cmaj.ca/collection) * [Sections](https://www.cmaj.ca/sections) * [Blog](http://cmajblogs.com/) * [Podcasts](https://www.cmaj.ca/page/multimedia/podcasts) * [COVID-19 articles](https://www.cmaj.ca/covid-19) * [Obituary notices](https://www.cmaj.ca/content/by/section/obituaries) * [Authors & Reviewers](https://www.cmaj.ca/page/content/overview-authors) * [Overview for authors](https://www.cmaj.ca/page/content/overview-authors) * [Submission guidelines](https://www.cmaj.ca/submission-guidelines) * [Submit a manuscript](https://mc.manuscriptcentral.com/cmaj) * [Forms](https://www.cmaj.ca/content/forms) * [Editorial process](https://www.cmaj.ca/content/editorial-process) * [Editorial policies](https://www.cmaj.ca/content/editorial-policies) * [Peer review process](https://www.cmaj.ca/content/peer-review-process) * [Publication fees](https://www.cmaj.ca/content/publication-fees) * [Reprint requests](https://www.cmaj.ca/content/reprint-requests) * [Open access](https://www.cmaj.ca/page/copyright) * [Patient engagement](https://www.cmaj.ca/Patient-Engagement) * [Physicians & Subscribers](https://www.cmaj.ca/content/about-us) * [Benefits for Canadian physicians](https://www.cmaj.ca/page/content/physician-benefits) * [CPD Credits for Canadian Physicians](https://www.cmaj.ca/page/content/earning-cpd-credits) * [Current Certified CPD Articles](https://www.cmaj.ca/content/current-certified-cpd-articles) * [Subscribe to email alerts](https://www.cmaj.ca/email-alerts) * [Subscribe to CMAJ print](https://www.cmaj.ca/subscribers) * [Subscription prices](https://www.cmaj.ca/page/subscription-prices) * [Obituary notices](https://www.cmaj.ca/obituaries) * [Email alerts](https://www.cmaj.ca/email-alerts) * [Subscribe to email alerts](https://www.cmaj.ca/email-alerts) * [JAMC](https://www.cmaj.ca/page/jamc/archives) * [À propos](https://www.cmaj.ca/page/apropos) * [Numéro en cours](https://www.cmaj.ca/novembre2026) * [Archives](https://www.cmaj.ca/page/jamc/archives) * [Sections](https://www.cmaj.ca/page/jamc-sections) * [Abonnement](https://www.cmaj.ca/page/abonnement) * [Alertes](https://www.cmaj.ca/page/alertes) * [Trousse média 2026](https://www.cmaj.ca/sites/default/files/additional-assets/site/pdfs/ads/2026/2026-JAMC-Media-Kit-r1.pdf) * [Avis de décès](https://www.cmaj.ca/avis-de-deces) * [CMAJ JOURNALS](https://www.cmaj.ca/) * [CMAJ Open](http://www.cmajopen.ca) * [CJS](http://www.canjsurg.ca) * [JAMC](https://www.cmaj.ca/page/apropos) [ ](https://www.facebook.com/CMAJ.JAMC "Follow on Facebook")[ ](https://www.instagram.com/cmaj.ca "Follow on Instagram")[ ](https://bsky.app/profile/cmaj.ca "Follow on Bluesky")[ ](https://www.buzzsprout.com/1815691 "Follow Podcast") [ Advanced Search ](https://www.cmaj.ca/search) * [Log in](https://www.cmaj.ca/openid-connect/sams-sigma/login-redirect?prompt=login&openid_connect_destination=/content/198/40/E1535) [![logo](https://www.cmaj.ca/sites/default/files/logo/cmaj-rgb_new_0_18.png)](https://www.cmaj.ca/) [![logo](https://www.cmaj.ca/sites/default/files/2025-05/cmaj-rgb_new.png)](https://www.cmaj.ca/) * Practice # Rheumatoid arthritis * Shahrukh T. Towheed Shahrukh T. Towheed * Department of Medicine, Division of Rheumatology, Queen’s University, Kingston, Ont. * MD * [Find this author on Google Scholar](https://www.cmaj.ca/lookup/google-scholar?link_type=googlescholar&gs_type=author&author\[0\]=Shahrukh%2BT.%2BTowheed "Open in new tab") * [Find this author on PubMed](https://www.cmaj.ca/lookup/external-ref?apath=/cmaj/198/40/E1535.atom&link_type=AUTHORSEARCH&access_num=Towheed%20ST) * [Search for this author on this site](https://www.cmaj.ca/search/?author1=Shahrukh%20T.%20Towheed) * and Akihiro Nakamura Akihiro Nakamura * Department of Medicine, Division of Rheumatology, Queen’s University, Kingston, Ont. * MD PhD * [Find this author on Google Scholar](https://www.cmaj.ca/lookup/google-scholar?link_type=googlescholar&gs_type=author&author\[0\]=Akihiro%2BNakamura "Open in new tab") * [Find this author on PubMed](https://www.cmaj.ca/lookup/external-ref?apath=/cmaj/198/40/E1535.atom&link_type=AUTHORSEARCH&access_num=Nakamura%20A) * [Search for this author on this site](https://www.cmaj.ca/search/?author1=Akihiro%20Nakamura) * CMAJ * November 16, 2026 * 198 * (40) * E1535; * DOI: https://doi.org/10.1503/cmaj.260500 [PDF](https://www.cmaj.ca/content/cmaj/198/40/E1535.full.pdf)[Help](https://scholar.google.com/scholar/help.html#access) * [Article](https://www.cmaj.ca/content/198/40/E1535#tab-group-article) * [Responses](https://www.cmaj.ca/content/198/40/E1535#tab-group-eletter) * [Metrics](https://www.cmaj.ca/content/198/40/E1535#tab-group-metrics) * [ PDF](https://www.cmaj.ca/content/cmaj/198/40/E1535.full.pdf) ## Rheumatoid arthritis (RA) is a common multisystem autoimmune disease[1](https://www.cmaj.ca/content/198/40/E1535#ref-1) About 0.5% to 1% of the population in Canada lives with RA.[1](https://www.cmaj.ca/content/198/40/E1535#ref-1) Indigenous Peoples in Canada are affected at approximately twofold higher rates than non-Indigenous people, and females are affected at threefold the rates of males.[2](https://www.cmaj.ca/content/198/40/E1535#ref-2) Peak incidence is between 50 and 60 years of age. Risk factors include smoking and family history of rheumatoid arthritis. ## The most common presentation is symmetric peripheral polyarthritis lasting 6 weeks or more Common sites include the wrists, metacarpophalangeal joints, proximal interphalangeal joints, knees, metatarsophalangeal joints, and atlantoaxial joint. Distal interphalangeal joints and the thoracolumbar spine are generally spared. Features include joint swelling, warmth, and 1 or more hours of morning stiffness. [3](https://www.cmaj.ca/content/198/40/E1535#ref-3) Differential diagnoses include psoriatic arthritis, crystalline arthropathies, and infectious arthropathies. ## Rheumatoid arthritis is a strong risk factor for cardiovascular disease[4](https://www.cmaj.ca/content/198/40/E1535#ref-4) Cardiovascular disease is the leading cause of death in patients with RA (standardized mortality ratio 1.50, 95% confidence interval 1.39 to 1.61, v. the general population).[4](https://www.cmaj.ca/content/198/40/E1535#ref-4) Mitigation of cardiovascular risk requires an aggressive approach involving primary care providers and rheumatologists to both optimize traditional risk factors (e.g., hypertension, diabetes, dyslipidemia, smoking) and control RA disease activity. ## Diagnosis is based on clinical, serologic, and imaging findings[3](https://www.cmaj.ca/content/198/40/E1535#ref-3) If history and examination are consistent with inflammatory arthritis, tests of rheumatoid factor and anti-cyclic citrullinated peptide (CCP) antibodies should be obtained. Positivity for rheumatoid factor has approximately 70% sensitivity and 80% specificity in diagnostic accuracy, while positivity for anti-CCP antibodies has approximately 70% sensitivity and 95% specificity.[5](https://www.cmaj.ca/content/198/40/E1535#ref-5) Radiographs may be normal in early disease, with characteristic findings later in disease progression.[3](https://www.cmaj.ca/content/198/40/E1535#ref-3) Musculoskeletal ultrasonography can provide real-time assessment of synovitis and is especially useful in early disease or unclear cases.[6](https://www.cmaj.ca/content/198/40/E1535#ref-6) ## Disease-modifying antirheumatic drugs (DMARDs) induce remission or low disease activity in approximately 75% of patients[3](https://www.cmaj.ca/content/198/40/E1535#ref-3) Classes include conventional synthetic DMARDs (e.g., hydroxychloroquine, sulfasalazine, methotrexate, leflunomide), biologic DMARDs (e.g., tumour necrosis factor-α inhibitors, interleukin-6 inhibitors), and targeted synthetic DMARDs (e.g., janus kinase inhibitors). Nonsteroidal anti-inflammatory drugs and corticosteroids are symptomatic therapies but are not disease-modifying agents.[3](https://www.cmaj.ca/content/198/40/E1535#ref-3) Most patients require long-term disease-modifying treatment to maintain remission.[3](https://www.cmaj.ca/content/198/40/E1535#ref-3) ## Footnotes * Competing interests: Akihiro Nakamura reports honoraria from Abbvie, Amgen, AstraZeneca, Celltrion, JAMP Pharma, Novartis, and UCB, and travel support from Celltrion and UCB. No other competing interests were declared. * This article has been peer reviewed. This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0) licence, which permits use, distribution and reproduction in any medium, provided that the original publication is properly cited, the use is noncommercial (i.e., research or educational use), and no modifications or adaptations are made. See: ## References 1. 1 [↵](https://www.cmaj.ca/content/198/40/E1535#xref-ref-1-1 "View reference in text") HassenNLacailleDXuA. National burden of rheumatoid arthritis in Canada, 1990–2019: findings from the Global Burden of Disease Study 2019 — a GBD collaborator-led study. RMD Open 2024;10:e003533. [Google Scholar](https://scholar.google.com/scholar_lookup?title=National%20burden%20of%20rheumatoid%20arthritis%20in%20Canada%2C%201990%E2%80%932019%3A%20findings%20from%20the%20Global%20Burden%20of%20Disease%20Study%202019%20%E2%80%94%20a%20GBD%20collaborator-led%20study&author=N%20Hassen&author=D%20Lacaille&author=A%20Xu&publication_year=2024&journal=RMD%20Open&volume=10&pages=e003533)[OpenURL](https://www.cmaj.ca/content/198/40/{openurl}?query=rft.jtitle%3DRMD+Open&rft_id%3Dinfo%3Adoi%2F10.1136%2Frmdopen-2023-003533&rft_id%3Dinfo%3Apmid%2F38216285&rft.genre%3Darticle&rft_val_fmt%3Dinfo%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&ctx_ver%3DZ39.88-2004&url_ver%3DZ39.88-2004&url_ctx_fmt%3Dinfo%3Aofi%2Ffmt%3Akev%3Amtx%3Actx)[CrossRef](https://dx.doi.org/10.1136/rmdopen-2023-003533)[Abstract/Full Text](https://www.cmaj.ca/lookup/ijlink?linkType=ABST&journalCode=rmdopen&resid=10/1/e003533)[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&db=pubmed&list_uids=38216285&dopt=Abstract) 2. 2 [↵](https://www.cmaj.ca/content/198/40/E1535#xref-ref-2-1 "View reference in text") McDougallCHurdKBarnabeC. Systematic review of rheumatic disease epidemiology in the indigenous populations of Canada, the United States, Australia, and New Zealand. Semin Arthritis Rheum 2017;46:675–86. [Google Scholar](https://scholar.google.com/scholar_lookup?title=Systematic%20review%20of%20rheumatic%20disease%20epidemiology%20in%20the%20indigenous%20populations%20of%20Canada%2C%20the%20United%20States%2C%20Australia%2C%20and%20New%20Zealand&author=C%20McDougall&author=K%20Hurd&author=C%20Barnabe&publication_year=2017&journal=Semin%20Arthritis%20Rheum&volume=46&pages=675-86)[OpenURL](https://www.cmaj.ca/content/198/40/{openurl}?query=rft.jtitle%3DSemin+Arthritis+Rheum&rft.volume%3D46&rft.spage%3D675&rft_id%3Dinfo%3Apmid%2F27914688&rft.genre%3Darticle&rft_val_fmt%3Dinfo%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&ctx_ver%3DZ39.88-2004&url_ver%3DZ39.88-2004&url_ctx_fmt%3Dinfo%3Aofi%2Ffmt%3Akev%3Amtx%3Actx)[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&db=pubmed&list_uids=27914688&dopt=Abstract) 3. 3 [↵](https://www.cmaj.ca/content/198/40/E1535#xref-ref-3-1 "View reference in text") AletahaDSmolenJS. Diagnosis and management of rheumatoid arthritis: a review. JAMA 2018;320:1360–72. [Google Scholar](https://scholar.google.com/scholar_lookup?title=Diagnosis%20and%20management%20of%20rheumatoid%20arthritis%3A%20a%20review&author=D%20Aletaha&author=JS%20Smolen&publication_year=2018&journal=JAMA&volume=320&pages=1360-72)[OpenURL](https://www.cmaj.ca/content/198/40/{openurl}?query=rft.jtitle%3DJAMA&rft.volume%3D320&rft.spage%3D1360&rft_id%3Dinfo%3Adoi%2F10.1001%2Fjama.2018.13103&rft_id%3Dinfo%3Apmid%2F30285183&rft.genre%3Darticle&rft_val_fmt%3Dinfo%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&ctx_ver%3DZ39.88-2004&url_ver%3DZ39.88-2004&url_ctx_fmt%3Dinfo%3Aofi%2Ffmt%3Akev%3Amtx%3Actx)[CrossRef](https://dx.doi.org/10.1001/jama.2018.13103)[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&db=pubmed&list_uids=30285183&dopt=Abstract) 4. 4 [↵](https://www.cmaj.ca/content/198/40/E1535#xref-ref-4-1 "View reference in text") EnglandBRThieleGMAndersonDR. Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications. BMJ 2018;361:k1036. [Google Scholar](https://scholar.google.com/scholar_lookup?title=Increased%20cardiovascular%20risk%20in%20rheumatoid%20arthritis%3A%20mechanisms%20and%20implications&author=BR%20England&author=GM%20Thiele&author=DR%20Anderson&publication_year=2018&journal=BMJ&volume=361&pages=k1036)[OpenURL](https://www.cmaj.ca/content/198/40/{openurl}?query=rft.jtitle%3DBMJ&rft_id%3Dinfo%3Adoi%2F10.1136%2Fbmj.k1036&rft_id%3Dinfo%3Apmid%2F29685876&rft.genre%3Darticle&rft_val_fmt%3Dinfo%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&ctx_ver%3DZ39.88-2004&url_ver%3DZ39.88-2004&url_ctx_fmt%3Dinfo%3Aofi%2Ffmt%3Akev%3Amtx%3Actx)[CrossRef](https://dx.doi.org/10.1136/bmj.k1036)[Abstract/Full Text](https://www.cmaj.ca/lookup/ijlink?linkType=ABST&journalCode=bmj&resid=361/apr23_6/k1036)[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&db=pubmed&list_uids=29685876&dopt=Abstract) 5. 5 [↵](https://www.cmaj.ca/content/198/40/E1535#xref-ref-5-1 "View reference in text") NishimuraKSugiyamaDKogataY. Meta-analysis: diagnostic accuracy of anti–cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 2007;146:797–808. [Google Scholar](https://scholar.google.com/scholar_lookup?title=Meta-analysis%3A%20diagnostic%20accuracy%20of%20anti%E2%80%93cyclic%20citrullinated%20peptide%20antibody%20and%20rheumatoid%20factor%20for%20rheumatoid%20arthritis&author=K%20Nishimura&author=D%20Sugiyama&author=Y%20Kogata&publication_year=2007&journal=Ann%20Intern%20Med&volume=146&pages=797-808)[OpenURL](https://www.cmaj.ca/content/198/40/{openurl}?query=rft.jtitle%3DAnnals+of+Internal+Medicine&rft.stitle%3DANN+INTERN+MED&rft.aulast%3DNishimura&rft.auinit1%3DK.&rft.volume%3D146&rft.issue%3D11&rft.spage%3D797&rft.epage%3D808&rft.atitle%3DMeta-analysis%3A+Diagnostic+Accuracy+of+Anti-Cyclic+Citrullinated+Peptide+Antibody+and+Rheumatoid+Factor+for+Rheumatoid+Arthritis&rft_id%3Dinfo%3Adoi%2F10.7326%2F0003-4819-146-11-200706050-00008&rft_id%3Dinfo%3Apmid%2F17548411&rft.genre%3Darticle&rft_val_fmt%3Dinfo%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&ctx_ver%3DZ39.88-2004&url_ver%3DZ39.88-2004&url_ctx_fmt%3Dinfo%3Aofi%2Ffmt%3Akev%3Amtx%3Actx)[CrossRef](https://dx.doi.org/10.7326/0003-4819-146-11-200706050-00008)[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&db=pubmed&list_uids=17548411&dopt=Abstract)[Web of Science](http://gateway.isiknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=Highwire&SrcApp=Highwire&DestLinkType=FullRecord&KeyUT=000247005200005&DestApp=WOS_CPL) 6. 6 [↵](https://www.cmaj.ca/content/198/40/E1535#xref-ref-6-1 "View reference in text") Di MatteoAMankiaKAzukizawaM. The role of musculoskeletal ultrasound in the rheumatoid arthritis continuum. Curr Rheumatol Rep 2020;22:41. [Google Scholar](https://scholar.google.com/scholar_lookup?title=The%20role%20of%20musculoskeletal%20ultrasound%20in%20the%20rheumatoid%20arthritis%20continuum&author=A%20Di%20Matteo&author=K%20Mankia&author=M%20Azukizawa&publication_year=2020&journal=Curr%20Rheumatol%20Rep&volume=22&pages=41)[OpenURL](https://www.cmaj.ca/content/198/40/{openurl}?query=rft.jtitle%3DCurr+Rheumatol+Rep&rft.volume%3D22&rft.spage%3D41&rft_id%3Dinfo%3Apmid%2F32562012&rft.genre%3Darticle&rft_val_fmt%3Dinfo%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&ctx_ver%3DZ39.88-2004&url_ver%3DZ39.88-2004&url_ctx_fmt%3Dinfo%3Aofi%2Ffmt%3Akev%3Amtx%3Actx)[PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&db=pubmed&list_uids=32562012&dopt=Abstract) ![Loading](https://www.cmaj.ca/modules/freebird/modules/highwire/highwire_markup/images/tab_loading.gif) ![Loading](https://www.cmaj.ca/modules/freebird/modules/highwire/highwire_markup/images/tab_loading.gif) [ PDF](https://www.cmaj.ca/content/cmaj/198/40/E1535.full.pdf) [Previous](https://www.cmaj.ca/content/198/40/E1532 "Paroxysmal nocturnal hemoglobinuria presenting as abdominal venous thrombosis in a 26-year-old man")[Next](https://www.cmaj.ca/content/198/40/E1536 "Deep neck abscess after fishbone injury") [Back to top](https://www.cmaj.ca/content/198/40/E1535#page) ### In This Issue [![ CMAJ ](https://www.cmaj.ca/sites/default/files/styles/large/public/highwire/cmaj/198/40.cover-source.jpg)](https://www.cmaj.ca/content/198/40 "CMAJ") ### [CMAJ](https://www.cmaj.ca/content/198/40 " CMAJ ") Vol. 198, Issue 40 16 Nov 2026 [ Table of Contents ](https://www.cmaj.ca/content/198/40 "Table of Contents")[ Index by author ](https://www.cmaj.ca/content/198/40/index-by-author "Index by author") ## Article tools * [ Respond to this article ](https://www.cmaj.ca/content/198/40/E1535#tab-group-eletter "Respond to this article") * [ Print ](https://www.cmaj.ca/custom-print/232611) * [ Download PDF ](https://www.cmaj.ca/content/cmaj/198/40/E1535.full.pdf) * [ Article Alerts ](https://www.cmaj.ca/content/198/40/E1535 "Article Alerts") #### Alerts for this Article User Name * Password * To sign up for email alerts or to access your current email alerts, enter your email address below: Email * * [ Email Article ](https://www.cmaj.ca/content/198/40/E1535 "Email This Article") #### Email This Article Thank you for your interest in spreading the word on CMAJ. NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following [Rheumatoid arthritis](https://www.cmaj.ca/content/198/40/E1535) Message Subject (Your Name) has sent you a message from CMAJ Message Body (Your Name) thought you would like to see the CMAJ web site. Your Personal Message CAPTCHA Please verify that you are a real person Close * [ Citation Tools ](https://www.cmaj.ca/content/198/40/E1535 "Citation Tools") #### Citation Tools ##### Rheumatoid arthritis * Shahrukh T. Towheed Shahrukh T. Towheed * and Akihiro Nakamura Akihiro Nakamura * CMAJ * November 16, 2026 * 198 * (40) * E1535; * DOI: 10.1503/cmaj.260500 #### Citation Manager Formats * [BibTeX](https://www.cmaj.ca/a
## Related Clinical Research

- [CXCL10 rs8878 genotype associates with preserved T cells and 30‑day survival in sepsis](https://medichelpline.com/clinical-feed/frontiers-in-immunology-1-cxcl10-rs8878-identifies-a-genotype-associated-immune-phenotype-linked-to-t.md)
- [COVID-19 Burden in Adults with Systemic Autoimmune Rheumatic Diseases in Quebec, 2020–2023](https://medichelpline.com/clinical-feed/medrxiv-15-comparative-burden-of-covid-19-in-adults-with-rheumatic-diseases-and.md)
- [Procoagulant effects of extracellular vesicles in patients with livedo reticularis](https://medichelpline.com/clinical-feed/frontiers-in-immunology-16-procoagulant-effects-of-extracellular-vesicles-in-patients-with-livedo.md)
- [Deep neck abscess after fishbone injury — article inaccessible; key data missing](https://medichelpline.com/clinical-feed/cmaj-3-deep-neck-abscess-after-fishbone-injury-practice.md)
- [Cardiovascular risk and mortality after statin initiation: achieved LDL and non‑HDL levels in a 3‑](https://medichelpline.com/clinical-feed/plos-medicine-0-risk-of-cardiovascular-events-and-mortality-associated-with-ldl-and-non-hdl.md)

## Navigation
- [← Back to Rheumatology Feed](https://medichelpline.com/clinical-feed/rheumatology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.